218 related articles for article (PubMed ID: 15283001)
1. Circadian variation in neuroendocrine response to L-dopa in patients with restless legs syndrome.
Garcia-Borreguero D; Larrosa O; Granizo JJ; de la Llave Y; Hening WA
Sleep; 2004 Jun; 27(4):669-73. PubMed ID: 15283001
[TBL] [Abstract][Full Text] [Related]
2. Circadian effects of dopaminergic treatment in restless legs syndrome.
Garcia-Borreguero D; Serrano C; Larrosa O; Granizo JJ
Sleep Med; 2004 Jul; 5(4):413-20. PubMed ID: 15223002
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of idiopathic and uremic restless legs syndrome with L-dopa--a double-blind cross-over study].
Wetter TC; Trenkwalder C; Stiasny K; Pollmächer T; Kazenwadel J; Kohnen R; Künzel M; Oertel WH
Wien Med Wochenschr; 1995; 145(17-18):525-7. PubMed ID: 8588396
[TBL] [Abstract][Full Text] [Related]
4. Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome.
Vetrugno R; Contin M; Baruzzi A; Provini F; Plazzi G; Montagna P
Mov Disord; 2006 Feb; 21(2):254-8. PubMed ID: 16200540
[TBL] [Abstract][Full Text] [Related]
5. Growth hormone response to low-dose apomorphine in restless legs syndrome.
Happe S; Bachmann CG; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
Growth Horm IGF Res; 2007 Aug; 17(4):323-7. PubMed ID: 17512770
[TBL] [Abstract][Full Text] [Related]
6. L-DOPA/carbidopa for nocturnal movement disorders in uremia.
Walker SL; Fine A; Kryger MH
Sleep; 1996 Apr; 19(3):214-8. PubMed ID: 8723378
[TBL] [Abstract][Full Text] [Related]
7. Validation of the "L-DOPA test" for diagnosis of restless legs syndrome.
Stiasny-Kolster K; Kohnen R; Möller JC; Trenkwalder C; Oertel WH
Mov Disord; 2006 Sep; 21(9):1333-9. PubMed ID: 16705685
[TBL] [Abstract][Full Text] [Related]
8. [Therapy of idiopathic and uremic restless legs syndrome].
Trenkwalder C; Stiasny K; Oertel WH
Nervenarzt; 1996 Apr; 67(4):265-76. PubMed ID: 8684504
[TBL] [Abstract][Full Text] [Related]
9. Low-dose pramipexole in the management of restless legs syndrome. An open label trial.
Stiasny-Kolster K; Oertel WH
Neuropsychobiology; 2004; 50(1):65-70. PubMed ID: 15179023
[TBL] [Abstract][Full Text] [Related]
10. One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome?
Trenkwalder C; Collado Seidel V; Kazenwadel J; Wetter TC; Oertel W; Selzer R; Kohnen R
Mov Disord; 2003 Oct; 18(10):1184-9. PubMed ID: 14534925
[TBL] [Abstract][Full Text] [Related]
11. Circadian changes in CSF dopaminergic measures in restless legs syndrome.
Earley CJ; Hyland K; Allen RP
Sleep Med; 2006 Apr; 7(3):263-8. PubMed ID: 16564215
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome.
Bliwise DL; Freeman A; Ingram CD; Rye DB; Chakravorty S; Watts RL
Sleep Med; 2005 Mar; 6(2):141-7. PubMed ID: 15716217
[TBL] [Abstract][Full Text] [Related]
13. Night-to-night variability in periodic leg movements in patients with restless legs syndrome.
Sforza E; Haba-Rubio J
Sleep Med; 2005 May; 6(3):259-67. PubMed ID: 15854857
[TBL] [Abstract][Full Text] [Related]
14. Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid.
Eisensehr I; Ehrenberg BL; Rogge Solti S; Noachtar S
J Neurol; 2004 May; 251(5):579-83. PubMed ID: 15164191
[TBL] [Abstract][Full Text] [Related]
15. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements.
Manconi M; Ferri R; Zucconi M; Oldani A; Fantini ML; Castronovo V; Ferini-Strambi L
Sleep Med; 2007 Aug; 8(5):491-7. PubMed ID: 17512780
[TBL] [Abstract][Full Text] [Related]
16. Treatment of restless leg syndrome with pergolide--an open clinical trial.
Winkelmann J; Wetter TC; Stiasny K; Oertel WH; Trenkwalder C
Mov Disord; 1998 May; 13(3):566-9. PubMed ID: 9613756
[TBL] [Abstract][Full Text] [Related]
17. Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome.
García-Borreguero D; Kohnen R; Högl B; Ferini-Strambi L; Hadjigeorgiou GM; Hornyak M; de Weerd AW; Happe S; Stiasny-Kolster K; Gschliesser V; Egatz R; Cabrero B; Frauscher B; Trenkwalder C; Hening WA; Allen RP
Sleep Med; 2007 Aug; 8(5):455-63. PubMed ID: 17543579
[TBL] [Abstract][Full Text] [Related]
18. [Restless-legs syndrome].
Karroum E; Konofal E; Arnulf I
Rev Neurol (Paris); 2008; 164(8-9):701-21. PubMed ID: 18656214
[TBL] [Abstract][Full Text] [Related]
19. A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms.
Collado-Seidel V; Kazenwadel J; Wetter TC; Kohnen R; Winkelmann J; Selzer R; Oertel WH; Trenkwalder C
Neurology; 1999 Jan; 52(2):285-90. PubMed ID: 9932945
[TBL] [Abstract][Full Text] [Related]
20. Transdermal lisuride: short-term efficacy and tolerability study in patients with severe restless legs syndrome.
Benes H
Sleep Med; 2006 Jan; 7(1):31-5. PubMed ID: 16194624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
